Satellos Bioscience Inc. (MSCL : TSX)
Common Stock
$7.89
CAD
-0.11 (-1.38%)
Last updated: 2026-06-16
MSCL
Satellos Bioscience Inc.
WealthAwesomePerformance
1 Day
-1.38%
1 Week
-4.94%
1 Month
-20.70%
YTD
-6.07%
Key Statistics
Market Cap
$166.65M
52W High
$18.98
52W Low
$6.36
P/E Ratio
-
50 Day MA
$9.63
200 Day MA
$10.17
Beta
1.17
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 6/16/2026 | $8.05 | $8.10 | $7.86 | $7.89 | $7.89 | 19,143 |
| 6/15/2026 | $8.10 | $8.27 | $8.00 | $8.00 | $8.00 | 11,569 |
| 6/12/2026 | $8.49 | $8.49 | $8.01 | $8.02 | $8.02 | 13,495 |
| 6/11/2026 | $8.29 | $8.42 | $7.97 | $8.02 | $8.02 | 13,621 |
| 6/10/2026 | $8.10 | $8.48 | $8.10 | $8.39 | $8.39 | 4,999 |
| 6/9/2026 | $7.92 | $8.65 | $7.92 | $8.30 | $8.30 | 12,062 |
| 6/8/2026 | $8.20 | $8.52 | $8.00 | $8.51 | $8.51 | 10,204 |
| 6/5/2026 | $8.22 | $8.40 | $7.90 | $8.20 | $8.20 | 22,469 |
| 6/4/2026 | $9.19 | $9.19 | $8.18 | $8.30 | $8.30 | 19,905 |
| 6/3/2026 | $9.80 | $9.80 | $8.31 | $8.31 | $8.31 | 31,089 |
Analyst Price Targets
Based on analyst covering MSCL
Wall Street analysts forecast MSCL stock price to rise 94.3% over the next 12 months.
Consensus
No RatingAvg. Target
C$15.33
+94.3% Upside
Current Price
C$7.89
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MSCL's historical volatility
30-Day Vol
62.5%
Annualized
90-Day Vol
85.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$6.60
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$7.43 | C$5.99 โ C$9.22 |
| 60 trading days | C$7.00 | C$5.16 โ C$9.50 |
| 90 trading days | C$6.60 | C$4.54 โ C$9.59 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Satellos Bioscience Inc.
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Financials
- Revenue (TTM)
- $0
- EBITDA
- $-30.02M
- Profit Margin
- 0.00%
- ROE (TTM)
- -50.74%
- EPS (Diluted)
- -2.51
- Book Value
- 4.73
๐ Recent Splits
1-for-12
Jan 30, 2026
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About MSCL
Articles Featuring MSCL.TO
Latest articles and analysis covering MSCL.TO
Why Satellos Bioscience Inc. stock is rising today
Satellos Bioscience Inc. has seen a 2.66% increase in its stock price today, closing at CA$8.10. This rise is attributed to investor optimism surrounding the company's ongoing clinical trials and strategic initiatives.
Why Satellos Bioscience Inc. stock is sliding today
Satellos Bioscience Inc. experienced a 2.50% decline in its stock price today, closing at CA$8.18. This drop raises questions about the company's market position and future performance as it navigates key clinical trials and strategic financial decisions.
Why Satellos Bioscience Inc. stock is gaining today
Satellos Bioscience Inc. has gained 1.65% today, closing at CA$8.65, as it continues to make strides in its clinical trials for Duchenne muscular dystrophy.
Why Satellos Bioscience Inc. stock is rising today
Satellos Bioscience Inc. shares rose by 3.54%, reflecting optimism surrounding its clinical programs. Investors are keenly watching the progress of SAT-3247, which targets Duchenne muscular dystrophy.
